High-throughput cell-based screening of 4910 known drugs and drug-like small molecules identifies disulfiram as an inhibitor of prostate cancer cell growth.
about
A conceptually new treatment approach for relapsed glioblastoma: coordinated undermining of survival paths with nine repurposed drugs (CUSP9) by the International Initiative for Accelerated Improvement of Glioblastoma CareNeuroglobin, a novel target for endogenous neuroprotection against stroke and neurodegenerative disordersEpigenetic modulators as therapeutic targets in prostate cancerHigh-throughput transcriptomic and RNAi analysis identifies AIM1, ERGIC1, TMED3 and TPX2 as potential drug targets in prostate cancerChemical biology drug sensitivity screen identifies sunitinib as synergistic agent with disulfiram in prostate cancer cellsCell-based screening identifies the active ingredients from Traditional Chinese Medicine formula Shixiao San as the inhibitors of atherosclerotic endothelial dysfunctionCancer Biology, Toxicology and Alternative Methods Development Go Hand-in-HandA transcriptomics data-driven gene space accurately predicts liver cytopathology and drug-induced liver injuryAn image-based, high-throughput screening assay for molecules that induce excess DNA replication in human cancer cellsComparison of the anti-cancer effect of Disulfiram and 5-Aza-CdR on pancreatic cancer cell line PANC-1Cell-based screening identifies paroxetine as an inhibitor of diabetic endothelial dysfunction.Identification of a novel inhibitor of triple-negative breast cancer cell growth by screening of a small-molecule library.Thiuram disulfides as pseudo-irreversible inhibitors of lymphoid tyrosine phosphatase.The role of small molecules in bone regeneration.Disulfiram modulated ROS-MAPK and NFκB pathways and targeted breast cancer cells with cancer stem cell-like propertiesAugmenting antitumor immune responses with epigenetic modifying agents.MicroRNA expression is differentially altered by xenobiotic drugs in different human cell lines.Concise review: bullseye: targeting cancer stem cells to improve the treatment of gliomas by repurposing disulfiram.Salinomycin inhibits prostate cancer growth and migration via induction of oxidative stress.Screen of FDA-approved drug library identifies maprotiline, an antibiofilm and antivirulence compound with QseC sensor-kinase dependent activity in Francisella novicida.Drug repositioning for personalized medicine.Delivery of disulfiram into breast cancer cells using folate-receptor-targeted PLGA-PEG nanoparticles: in vitro and in vivo investigations.The cytotoxic mechanisms of disulfiram and copper(ii) in cancer cells.Pharmacodynamic study of disulfiram in men with non-metastatic recurrent prostate cancer.High-throughput screen identifies disulfiram as a potential therapeutic for triple-negative breast cancer cells: interaction with IQ motif-containing factorsTargeting epigenetic mechanisms for clinical translation: enhancing the efficacy of tumor immunotherapies.The therapeutic potential of vaginal drug delivery in the treatment of cervical cancer.Disulfiram and its novel derivative sensitize prostate cancer cells to the growth regulatory mechanisms of the cell by re-expressing the epigenetically repressed tumor suppressor-estrogen receptor β.Drug discovery in advanced prostate cancer: translating biology into therapy.Disulfiram-loaded immediate and extended release vaginal tablets for the localised treatment of cervical cancer.ALDH1A1 mediates resistance of diffuse large B cell lymphoma to the CHOP regimen.Copper signaling axis as a target for prostate cancer therapeutics.Cytotoxic effect of disulfiram/copper on human glioblastoma cell lines and ALDH-positive cancer-stem-like cellsVaginal drug delivery for the localised treatment of cervical cancer.A novel screen using the Reck tumor suppressor gene promoter detects both conventional and metastasis-suppressing anticancer drugs.Disulfiram is a DNA demethylating agent and inhibits prostate cancer cell growth.Arachidonic acid pathway members PLA2G7, HPGD, EPHX2, and CYP4F8 identified as putative novel therapeutic targets in prostate cancer.High-throughput cell-based compound screen identifies pinosylvin methyl ether and tanshinone IIA as inhibitors of castration-resistant prostate cancer.Targeting the cancer stem cell marker, aldehyde dehydrogenase 1, to circumvent cisplatin resistance in NSCLCProtein-protein interaction network analysis in chronic obstructive pulmonary disease.
P2860
Q26851160-796CF32C-1893-4879-A959-9FA5BB16F8FEQ26865964-873DCBDD-542D-452E-83E5-C2D0C28546C7Q28071912-6B01478C-4E7A-4A87-AECF-BD83EC319A79Q28480861-7A63DEFE-560A-4580-8D18-BE3BB550C5B1Q28484299-203007AC-FD54-4917-AF4F-0E477D8D70A7Q28543569-13E9CE3B-9E16-4B1C-9116-BC498C699337Q28549191-9C704424-334A-43D2-9D96-09CE67B5DD2EQ31724476-B2B4D56F-C262-43D9-BADE-CE8E2DF9049FQ33800817-A4A2C855-9DA8-4F25-8BCB-A8C6A8214EEAQ34170221-0357AD99-15C5-4F8D-A923-409BFFBAD05EQ34504222-B280358A-D661-4985-B469-7441ACDA67EBQ34606101-59F32518-88EE-4CA0-8362-DCD0C905D932Q34844499-D09CE767-F459-4DA9-9964-941DBF68E175Q34991901-B22E2832-1553-40CA-B932-326740B002D9Q35006770-32800365-C0C0-417E-8589-45D8AB7F9DB2Q35048054-498F569B-ED15-4CA3-9C0B-9FE8B6AC2E29Q35171243-7ED88F38-6362-43E3-8910-740AB9497FC5Q35542866-A1A23888-BFEE-4D38-AC33-37F99C9E3388Q35653860-5BCF11D5-3321-4DDC-B295-347A455921DCQ35686324-C3D59347-9CD8-4D9B-9EA9-0113BC9D3FDAQ36245193-02E51FF8-990B-40CA-A16E-E846CA558F8AQ36820304-F4565F2B-4E03-43F5-957A-3C8224CF3F75Q37264685-9E524303-DDC5-46C1-BC88-62DD2DE1BCD0Q37315686-6B5956A2-BC0D-41C3-B21D-2BA1FA9ABC54Q37420053-F7F8ED5B-8A2F-40E5-96D4-CA372AB95A2AQ38159805-10BB6303-6C33-47C8-9B3B-1DC698670CE4Q38498021-4DCC163D-B535-4079-992A-0D42E957D63EQ38817309-ABDD5E7E-DEF6-4FB2-A4BC-F97ECA144EA3Q38839110-E62AD8C8-03BC-460C-B3AA-FA351B402D75Q38930082-EFCD6027-B05F-437E-BAD8-3D1B5647FED9Q38945255-F6550409-6340-4C2A-9230-2A50312F1B97Q38947366-23CE9C47-E5FB-4E45-AB0C-81719453C241Q39266662-52BCAAC0-3488-458A-AB0A-3380129FAEA6Q39361267-B6282307-4E42-43C2-8F02-85F320D804C5Q39595777-B9534216-F78A-4F65-BBEC-48F7D6D32D44Q39660971-08275301-23FD-4FD3-BABC-136EB35A8B09Q42045155-9FC15E6A-71B3-4807-B54E-DCDDF7273526Q42098076-DB145779-B32D-4951-B61E-6B22224FE928Q42700773-481511B0-DDAC-437C-B343-F1F38D4AB652Q45682609-108AF541-5812-40CE-89D8-993360902413
P2860
High-throughput cell-based screening of 4910 known drugs and drug-like small molecules identifies disulfiram as an inhibitor of prostate cancer cell growth.
description
2009 nî lūn-bûn
@nan
2009 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
High-throughput cell-based scr ...... f prostate cancer cell growth.
@ast
High-throughput cell-based scr ...... f prostate cancer cell growth.
@en
type
label
High-throughput cell-based scr ...... f prostate cancer cell growth.
@ast
High-throughput cell-based scr ...... f prostate cancer cell growth.
@en
prefLabel
High-throughput cell-based scr ...... f prostate cancer cell growth.
@ast
High-throughput cell-based scr ...... f prostate cancer cell growth.
@en
P2093
P50
P1476
High-throughput cell-based scr ...... f prostate cancer cell growth.
@en
P2093
Kristiina Iljin
Pasi Halonen
Paula Vainio
Roland C Grafström
P304
P356
10.1158/1078-0432.CCR-09-1035
P407
P577
2009-09-29T00:00:00Z